This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

01/17/14 - 03:30 PM EST

Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline updates. Historically, biotechnology stocks have outperformed during this conference week -- and we have seen broad-based strength from the group -- but more importantly, investors are provided with a reiteration of some of the strong themes that will dominate 2014...


Buy Best Names of Shale Revolution on Pullbacks: Best Acreage and Company-Specific Catalysts

01/16/14 - 07:27 PM EST

2013 was the year of the Permian Basin, 2012 was the year of the Eagle Ford, and 2011 was the year of the Bakken. What is the theme for 2014? At this point, most of the plays have been discovered, with even new finds in the Utica "known." So key is choosing the names with the BEST acreage -- because they will continue to outperform....


Another Side of the Security Play: LifeLock

01/16/14 - 03:55 PM EST

Another side of the security play: Keep an eye out for LifeLock's interview on Mad Money Tonight


I Prefer a Bold Marissa Mayer

01/16/14 - 02:17 PM EST

Yes, Yahoo CEO Marissa Mayer's decision to fire COO Henrique de Castro after only a 15-month tenure reveals that Yahoo's core business continues to struggle. But is this news? No! Mayer has the benefit of taking risks in the core business (think: expensive Tumblr acquisition for example), and being brutal at times when it comes to management decisions, because of the Alibaba halo....


Retail Battlefield: 3 Stocks That Are Buyable Here

01/16/14 - 02:14 PM EST

The bloodbath in retail in the last couple of weeks doesn't seem to want to come to an end, with a dismal report from Best Buy, one of the best performers in 2013, today. This week marked one of the most pessimistic ICR XChange conferences in recent years. So is anything buyable? Here are three names that I think are...


Think 2013 Was a Big IPO year? Watch Out For 2014...

01/16/14 - 08:55 AM EST

While we don't have pricing details yet for many of 2014's hyped potential IPOs, it's key to know which names to have on your radar. This year holds a good deal of promise for the IPO market, where investors want to seek new names to play strong themes and with an appetite for growth...


Market Movers: Markets Rise as Bank of America Reports Strong Numbers

01/15/14 - 01:06 PM EST

U.S. markets are up today, as Bank of America's profit surged. Tesla is rising further after a strong Model S report yesterday. 3D names, like 3D Systems and Stratasys , are falling after peer ExOne reported disappointing numbers. Burberry is trading up after strong retail sales growth and Apple is in focus as CEO Tim Cook held a press conference in China for the company's new agreement with China Mobile. General Motors GM announces its $1.20 per share annual dividend....


Why Google Can Pay Whatever It Wants

01/14/14 - 07:02 PM EST

When not talking about potential privacy issues, Many analysts and commentators have been balking at the price Google paid for Nest. A whopping $3.2 billion in cash ain't cheap, after all.But one thing not enough people are saying? Why not! Google ended last quarter with about $56.5 billion in cash. Even though the company is investing in research & development and its own growth, its $12 billion annual free cash flow generation still leaves a lot on the table.


Chart of The Day: Beam

01/13/14 - 06:07 PM EST

Breaking up ain't hard to do. The celebration of Beam's chart is more than a one day spike - it is years of value creation


Morning Movers: Beam Up on Takeover; Retailers Disappoint; Wendy's Heads Higher

01/13/14 - 01:01 PM EST

Today kicked off with a 'merger Monday' takeover of Beam by Japan's Suntory and was rounded out by disappointing retail data from the likes of Lululemon, Express, Ascena and SodaStream. In food, we got another smart tuck-in acquisition from health play Hain Celestial and good numbers out of Wendys...


Nicole Urken is Research Director of Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money." Nicole also supports Jim's other endeavors including "Squawk on the Street,", and his latest best-selling book "Get Rich Carefully."

Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.


DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Nicole's Tweets

Brokerage Partners

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs